[go: up one dir, main page]

MX2009009624A - Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia. - Google Patents

Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia.

Info

Publication number
MX2009009624A
MX2009009624A MX2009009624A MX2009009624A MX2009009624A MX 2009009624 A MX2009009624 A MX 2009009624A MX 2009009624 A MX2009009624 A MX 2009009624A MX 2009009624 A MX2009009624 A MX 2009009624A MX 2009009624 A MX2009009624 A MX 2009009624A
Authority
MX
Mexico
Prior art keywords
fibromyalgia
treatment
droxidopa
methods
pharmaceutical composition
Prior art date
Application number
MX2009009624A
Other languages
English (en)
Inventor
Michael J Roberts
Simon Pedder
Original Assignee
Chelsea Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chelsea Therapeutics Inc filed Critical Chelsea Therapeutics Inc
Publication of MX2009009624A publication Critical patent/MX2009009624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para tratar fibromialgia u otras enfermedades o padecimientos que ocasionan dolor generalizado y/o fatiga. En particular, la invención proporciona composiciones farmacéuticas que comprenden droxidopa sola, o en combinación con uno o más agentes activos adicionales, que pueden usarse en los métodos inventivos. Los métodos de tratamiento pueden comprender tratar, prevenir, reducir, o eliminar una diversidad de síntomas reconocidos como indicativos de fibromialgia, tales como dolor crónico, alodinia, hiperalgesia, fatiga, alteración del sueño, y depresión.
MX2009009624A 2007-03-09 2008-03-07 Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia. MX2009009624A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89403007P 2007-03-09 2007-03-09
PCT/US2008/056255 WO2008112562A1 (en) 2007-03-09 2008-03-07 Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia

Publications (1)

Publication Number Publication Date
MX2009009624A true MX2009009624A (es) 2009-12-11

Family

ID=39666215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009624A MX2009009624A (es) 2007-03-09 2008-03-07 Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia.

Country Status (12)

Country Link
US (2) US8008285B2 (es)
EP (2) EP2134335B1 (es)
JP (1) JP2010520885A (es)
KR (1) KR20100014392A (es)
CN (1) CN101657193A (es)
AU (1) AU2008226541B2 (es)
BR (1) BRPI0808647A2 (es)
CA (1) CA2680272A1 (es)
ES (2) ES2480966T3 (es)
MX (1) MX2009009624A (es)
NZ (1) NZ579368A (es)
WO (1) WO2008112562A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5620907B2 (ja) * 2008-06-19 2014-11-05 エルテーエスローマン テラピー−ジステーメ アーゲー カチオン性活性剤の経皮送達のための組成物
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
JP5989319B2 (ja) * 2011-10-06 2016-09-07 ライオン株式会社 睡眠の質改善剤
CN103086906B (zh) * 2011-11-03 2015-04-01 重庆圣华曦药业股份有限公司 屈昔多巴的晶型及其制备方法
US10340034B2 (en) 2011-12-30 2019-07-02 Elwha Llc Evidence-based healthcare information management protocols
US10552581B2 (en) 2011-12-30 2020-02-04 Elwha Llc Evidence-based healthcare information management protocols
US10559380B2 (en) 2011-12-30 2020-02-11 Elwha Llc Evidence-based healthcare information management protocols
US10475142B2 (en) 2011-12-30 2019-11-12 Elwha Llc Evidence-based healthcare information management protocols
US10528913B2 (en) 2011-12-30 2020-01-07 Elwha Llc Evidence-based healthcare information management protocols
US10679309B2 (en) 2011-12-30 2020-06-09 Elwha Llc Evidence-based healthcare information management protocols
US20130173296A1 (en) 2011-12-30 2013-07-04 Elwha LLC, a limited liability company of the State of Delaware Evidence-based healthcare information management protocols
EP2809315A1 (en) 2012-01-31 2014-12-10 Lundbeck Na Ltd Improving postural stability administering droxidopa
WO2013142093A1 (en) 2012-03-20 2013-09-26 Chelsea Therapeutics, Inc. Method for the synthesis of droxidopa
JP5995803B2 (ja) * 2012-08-23 2016-09-21 森永乳業株式会社 カテコール−ｏ−メチルトランスフェラーゼ阻害剤
EA201600093A1 (ru) 2013-07-08 2016-08-31 Ауспекс Фармасьютикалс, Инк. Дигидроксифенильные нейромедиаторные соединения, композиции и способы
PE20180021A1 (es) * 2015-02-20 2018-01-09 Univ Oregon Health & Science Derivados de sobetiroma
CN104726395B (zh) * 2015-03-20 2018-03-23 深圳市人民医院 一种诱导人诱导多能干细胞定向分化为胰腺细胞的方法
US20180360808A1 (en) * 2015-12-07 2018-12-20 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
GB201521541D0 (en) * 2015-12-07 2016-01-20 Proximagen Ltd New therapeutic uses of enzyme inhibitors
CN105944083A (zh) * 2016-05-03 2016-09-21 董桂芬 一种用于治疗纤维肌痛综合症的复方护理剂及其制备方法
GB201709136D0 (en) * 2017-06-08 2017-07-26 Proximagen Ltd New therapeutic uses of enzyme inhibitors
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CN113631157A (zh) * 2019-02-17 2021-11-09 诺拉威尔治疗公司 用于治疗抑郁症和其它病症的组合物和方法
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
US12433904B2 (en) 2019-04-17 2025-10-07 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
CN115279359A (zh) 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
EP4397371A3 (en) 2020-05-19 2024-10-30 Cybin IRL Limited Deuterated tryptamine derivatives and methods of use
CN115916740A (zh) 2020-06-17 2023-04-04 速通医疗公司 拟甲状腺素药

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920728A (en) 1973-08-22 1975-11-18 Hoffmann La Roche Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine
JPS5419931A (en) 1977-07-11 1979-02-15 Sumitomo Chem Co Ltd Separation of threo, erythro-3-(3,4-dibenzyloxyphenyl)serines
US4319046A (en) 1977-07-22 1982-03-09 The Sherwin-Williams Company Preparation of 1,2 diaminobenzene by high pressure acid hydrolysis of benzemidazolone
JPS5629551A (en) 1979-08-20 1981-03-24 Sumitomo Chem Co Ltd Preparation of optically active threo-3- 3,4- dihydroxyphenyl serine
JPS56104815A (en) 1980-01-23 1981-08-20 Sumitomo Chem Co Ltd Remedy for peripheral orthostatic hypotension
US4421767A (en) 1981-06-01 1983-12-20 Merrell Toraude Et Compagnie Compounds and methods for treating depression
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
US4480109A (en) 1982-01-14 1984-10-30 Sumitomo Chemical Company, Limited Process for producing threo-3-(3,4-dihydroxyphenyl)serine
CA1223602A (en) 1983-05-25 1987-06-30 Naohito Ohashi Process for producing 3-(3,4-dihydroxyphenyl) serine
JPS6067420A (ja) 1983-09-22 1985-04-17 Sumitomo Chem Co Ltd 精神運動興奮抑制剤
JPS6098995A (ja) 1983-11-04 1985-06-01 Microbial Chem Res Found 光学活性３−（３，４−ジヒドロキシフエニル）セリン，およびその誘導体の製造法
JPS6185318A (ja) 1984-10-04 1986-04-30 Sumitomo Seiyaku Kk 利尿薬
US5288898A (en) 1985-09-30 1994-02-22 Zaidan Hojim Biseibutsu Kagaku Kenkyu Kai N-methylphenylserine alkyl ester derivatives and uses thereof
JPS62106015A (ja) 1985-10-31 1987-05-16 Sumitomo Pharmaceut Co Ltd 抗痴呆薬
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
GB8720600D0 (en) 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US5240930A (en) 1987-09-02 1993-08-31 National Research Development Corporation Pharmaceutical compositions for treatment of depression and low blood pressure
US5015564A (en) 1988-12-23 1991-05-14 Eastman Kodak Company Stabilizatin of precipitated dispersions of hydrophobic couplers, surfactants and polymers
JP2603566B2 (ja) 1991-03-27 1997-04-23 住友製薬株式会社 尿失禁治療剤
JP3559572B2 (ja) 1993-01-29 2004-09-02 住友製薬株式会社 急性痛および慢性痛用鎮痛剤
JP3764179B2 (ja) 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
DE19619510A1 (de) 1995-05-18 1996-11-21 Sumitomo Chemical Co Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin
GB9510481D0 (en) 1995-05-24 1995-07-19 Orion Yhtymae Oy New catechol derivatives
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
JPH115738A (ja) 1997-06-15 1999-01-12 Katsuhiro Nishino 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤
US6033993A (en) 1997-09-23 2000-03-07 Olin Microelectronic Chemicals, Inc. Process for removing residues from a semiconductor substrate
FR2777781B1 (fr) 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20020177593A1 (en) 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
WO2000027385A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd., Et Al. Dispersible compositions containing l-dopa ethyl ester
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
SK286667B6 (sk) 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu chronického únavového syndrómu
US20010047032A1 (en) 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
CA2425125A1 (en) 2000-10-12 2002-07-25 Kjell A. Svensson Method of treating parkinson's disease
CA2463624A1 (en) 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP1490073A4 (en) 2002-03-21 2006-02-01 Martin C Hinz SEGMENT OPTIMIZATION TECHNOLOGY FOR THE SEROTONIN AND CATECHOLAMINE SYSTEM
AU2003275433A1 (en) * 2002-10-07 2004-05-04 Synergia Pharma, Inc. Compositions and methods for treating pain
US20060019940A1 (en) 2002-12-20 2006-01-26 Baxter Andrew D Novel benzoxazocines and their therapeutic use
WO2004100929A1 (en) * 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US7897639B2 (en) 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
KR100458983B1 (ko) 2004-03-05 2004-12-03 주식회사 에스텍파마 광학적으로 활성인 세린 유도체의 제조방법
WO2005102366A2 (en) 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
RU2008135326A (ru) 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
ES2383768T3 (es) * 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa

Also Published As

Publication number Publication date
BRPI0808647A2 (pt) 2014-08-12
EP2134335B1 (en) 2014-04-23
KR20100014392A (ko) 2010-02-10
EP2468271A1 (en) 2012-06-27
ES2480966T3 (es) 2014-07-29
CN101657193A (zh) 2010-02-24
US8008285B2 (en) 2011-08-30
US20110259786A1 (en) 2011-10-27
EP2134335A1 (en) 2009-12-23
CA2680272A1 (en) 2008-09-18
WO2008112562A1 (en) 2008-09-18
JP2010520885A (ja) 2010-06-17
EP2468271B1 (en) 2014-07-16
NZ579368A (en) 2012-03-30
AU2008226541B2 (en) 2013-05-09
ES2500053T3 (es) 2014-09-29
US20080221170A1 (en) 2008-09-11
AU2008226541A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
MX2009009624A (es) Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia.
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
MX342128B (es) Compuestos farmaceuticos.
MX2010005343A (es) Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina.
WO2006128032A3 (en) Compositions and methods for the prevention and treatment of conditions associated with inflammation
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
MX2010000380A (es) Formulacion de proteina de fusion glp-1-fc.
WO2009027346A3 (de) 17beta-hydroxysteroid-dehydrogenase-typ1-inhibitoren zur behandlung hormonabhängiger erkrankungen
JO3358B1 (ar) معالجات حساسية العيون
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2009005114A (es) Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
TNSN08277A1 (en) Materials and methods for treating chronic fibrotic disease
WO2008010991A3 (en) Methods and compositions for the treatment of cancer
WO2007046102A3 (en) Methods for the treatment of hyperhidrosis
MY156275A (en) Compositions comprising tramadol and celecoxib in the treatment of pain
WO2007058990A3 (en) Therapy using cytokine inhibitors
MX2012006629A (es) Microorganismos probioticos como agentes activos contra cambios en microrelieve de la piel.
WO2007146730A3 (en) Deacetylase inhibitor therapy
CA2767833C (en) N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
MX2009000359A (es) Metodos paratratar y limitar trastornos fibroticos y queloides.

Legal Events

Date Code Title Description
FG Grant or registration